Research Signal – Source date 2022-02-23
Living longer with HIV has changed the central question in long-term care. Antiretroviral therapy has enabled people with HIV, the virus that attacks the immune system, to live longer and healthier lives than many people diagnosed during the earlier years of the pandemic. Yet several cohorts described in a February 2022 Series paper still show a greater burden of age-related illness among people with HIV than among people without HIV.
That burden is often described as multimorbidity, meaning that a person is living with several chronic conditions at the same time. Cancer, cardiovascular disease, neurocognitive impairment, frailty-related problems, and reduced physical function can affect quality of life. The pattern raises an important question: does HIV make the whole body age faster, or are different biological processes and life circumstances shaping different health trajectories?
The paper, titled Biological ageing with HIV infection: evaluating the geroscience hypothesis, does not assign every person with HIV a fixed amount of extra biological age. Instead, it brings together research on several mechanisms that may contribute to disease and loss of function, then places those mechanisms alongside the body’s reserves and ability to recover.
Aging is not a single process inside the body
The paper organizes its discussion around four major gerodrivers: macromolecular damage, cellular senescence, inflammation, and stem-cell dysfunction. These domains overlap, but they are not interchangeable. Evidence also differs across them, ranging from laboratory and animal findings to human associations and clinical studies in different populations. The examples therefore illustrate possible connections rather than forming one test of the entire model.
Macromolecular damage includes changes to structures such as DNA and mitochondria. Shorter telomeres have been observed in blood cells and lung epithelial cells from people with HIV compared with people without HIV, and shorter blood-cell telomeres have been associated with cardiovascular risk in people with HIV. Those observations make telomere length relevant to the discussion, but they do not by themselves show that telomere shortening causes a uniform rate of aging across the body. Epidemiological and clinical data still leave causation and correlation difficult to separate.
The mitochondrial evidence also has a treatment history. Earlier nucleoside reverse transcriptase inhibitors were known to affect mitochondrial DNA polymerase, with mitochondrial mutations and reduced oxidative phosphorylation in skeletal muscle described as early evidence of advanced aging in people with HIV. Research on contemporary nucleoside reverse transcriptase inhibitors suggests that mitochondrial effects may occur in other cell types, including renal cells and adipocytes, but the information is more limited and cell-specific. The paper uses this history to argue for studying HIV, treatment exposure, and aging together rather than treating any one of them as a complete explanation.
Cellular senescence adds another layer. Chronic exposure to HIV or other pathogenic antigens can drive some T cells toward a state of replicative senescence. This state resembles cellular senescence in some respects but is not identical to it. The paper also discusses evidence linking cellular senescence and persistent inflammation with multimorbidity, while noting that there is no universal biomarker for senescence.
Inflammation can remain elevated even when viremia is controlled. The paper describes higher concentrations of several inflammatory and immune-activation markers in people with HIV receiving effective antiretroviral therapy than in people without HIV. These elevations have been linked with adverse functional outcomes. The contribution of inflammation in tissues and compartments beyond peripheral blood remains less clear, as do the exact pathways connecting inflammatory signals to particular diseases.
Stem-cell dysfunction concerns the ability to maintain and renew tissues. The paper describes losses in blood-forming progenitors and naive T cells, evidence related to muscle aging signatures and bioenergetic capacity, a higher prevalence of inflammation-related clonal hematopoiesis in one comparison, and impairment of mesenchymal stem cells involved in bone formation. Evidence involving neurogenesis comes from transgenic mice rather than from a direct measure of aging in people with HIV. Whether these losses mirror normal aging in people without HIV requires carefully designed comparative research.
Reserve determines how much strain a person can absorb
A list of damaging processes is not enough to explain whether someone remains mobile, cognitively able, or independent. The paper’s conceptual contribution is to place those processes beside geroprotectors, including healthy aging, physiological reserve, intrinsic capacity, and resilience.
Physiological reserve is the capacity available for maintaining metabolic and organ stability, physical activity, and other energy-demanding tasks. Intrinsic capacity brings several functional domains into view, including mobility, cognition, psychological health, vitality, and sensory abilities. Resilience describes the ability to recover, adapt, and continue functioning after stress. These ideas shift attention from the presence of biological strain alone to what the body can still do when illness, treatment, injury, or other demands occur.
The proposed model uses a descending series of pools to represent shrinking homeostatic capacity over the life course. Gerodrivers place pressure on those reserves, while geroprotectors are proposed to preserve or support them. HIV and age-related changes may also affect communication between organs, producing asynchronous aging in which tissues and systems do not change at the same pace.
This is a conceptual model, not a validated formula for predicting an individual’s future. Its value is in asking a broader clinical question. Alongside molecular damage and inflammation, how much reserve does a person have, which capacities are being lost, and how well can those capacities recover? Two people with similar laboratory signals may not have the same mobility, cognition, or resilience. Conversely, a functional problem may become important before a molecular measure provides a complete explanation.
A biological-age score cannot answer every health question
The paper discusses several possible ways to measure biological aging, including epigenetic changes, cellular markers, telomere length, and composite scores. Some studies cited in the paper found differences in epigenetic age between people with HIV and uninfected people, while other work reported smaller age acceleration and reductions in the difference with antiretroviral therapy. These estimates can be useful for studying biological processes, but an age estimate from blood or brain tissue is not a whole-person biological age and is not, by itself, a prognosis for an individual.
The same caution applies to composite measures. A score that combines molecular or physiological signals may cover more ground than one biomarker, yet it still may not capture all relevant processes, functional reserves, or resilience. A measure associated with risk is not automatically a measure of cause, and a change in a biomarker is not automatically a change in everyday independence.
Clinical assessments ask a different kind of question. Comprehensive geriatric assessment can include evaluation of geriatric syndromes and referral to geriatric care. Frailty measures, multimorbidity indices, and the Veterans Aging Cohort Study Index have also been discussed or applied in the context of HIV care, while newer approaches involving intrinsic capacity and resilience are still being adapted. These tools focus more directly on function, vulnerability, and care needs than a molecular age estimate does.
The future challenge is to connect these levels without collapsing them. A useful assessment for people aging with HIV would need to relate biological processes to distinct trajectories of functional ability, reserve, and recovery. It would also need to work across the settings where people receive care, not only in highly resourced research environments.
Potential treatments have different targets and different proof requirements
The therapeutic possibilities in the paper show why the word benefit needs to be used precisely. Senolytic approaches aim to clear senescent cells, often by promoting their death. Senomorphic approaches do not clear those cells; instead, they seek to limit the inflammatory secretions associated with the senescent state. The two strategies target different processes and would not necessarily produce the same biological or functional result.
Some examples are especially exploratory. A combination of quercetin and dasatinib was described as safe and associated with some improvement in physical function in people with idiopathic pulmonary fibrosis. That population and outcome do not establish the safety or benefit of senolytic treatment for people aging with HIV. Laboratory work with venetoclax has explored whether selective elimination of infected cells could reduce the HIV reservoir. Histone deacetylase inhibitors have also been studied in latency-reversal approaches. In examples discussed by the paper, a temporary increase in viral RNA did not automatically produce a reservoir reduction, and increased T-cell activation could accompany the intervention.
These outcomes answer different questions. Changing viral activity, reducing the size of a reservoir, lowering an inflammatory marker, and preserving physical function are not interchangeable signs of success. A drug may affect one target without improving another. The distinction matters especially when an intervention is being considered for both HIV-related biology and aging-related decline.
Non-pharmacological approaches have their own pattern of evidence. Exercise and physical activity can support muscle mass, cardiovascular endurance, and strength, but studies have found mixed effects on inflammatory biomarkers. Nutrition combined with exercise appears relevant to frailty in the limited research described, while evidence for micronutrient replacement, calorie restriction, microbiome interventions, stress reduction, and meditation remains varied across outcomes. Better mental health does not necessarily come with a measurable change in immune markers, just as a biomarker change does not necessarily mean that a person can walk farther or manage daily life more independently.
Treatment and social conditions shape the aging story
The paper argues that an aging model for people with HIV needs to integrate biology with the conditions under which people live and receive care. Its research agenda includes geography, ancestry, sex, socioeconomic circumstances, stigma, access to antiretroviral therapy, adherence, and treatment effects. The authors call for studies to clarify how these interacting factors contribute to adverse outcomes and how understanding them could improve health and care delivery.
The paper identifies resource-poor settings as places where the burden of multimorbidity is exacerbated. It does not reduce that burden to individual health choices: its research agenda includes socioeconomic circumstances, stigma, and access to care. It also calls for clinical studies designed to ensure equal access to care and treatment while testing interventions aimed at aging-related pathways.
The same context also limits simple comparisons between people with and without HIV. Differences in treatment history, co-infections, lifestyle, chronic stress, healthcare access, and the timing of diagnosis can affect outcomes alongside HIV-related mechanisms. The paper’s proposed research agenda therefore asks for models that integrate primary biological aging, secondary influences such as lifestyle, and tertiary effects from comorbidity and co-infection.
What this could mean for healthier lives with HIV
The prospective benefit of this approach is more practical than assigning a new number to someone’s age. If the proposed connections between gerodrivers, reserves, and resilience hold up, HIV care could become better at identifying when mobility, cognition, vitality, or recovery capacity is beginning to narrow, then responding to shared contributors to several chronic illnesses.
For people aging with HIV, that could mean care designed around preserving function and independence as well as controlling the virus. The promise remains conditional. Interventions would need to produce meaningful functional and clinical benefits in people with HIV, and those benefits would need to be accessible across different care settings. A conceptual model cannot deliver that outcome by itself, but it can widen the goal of successful HIV treatment from longer survival toward healthier years in which people can continue to recover, adapt, and live independently.
Key Sources
- Primary source: Biological ageing with HIV infection: evaluating the geroscience hypothesis.
DOI or Journal Page · Peer-Reviewed Paper · 2022-02-23
Keep exploring